Coherus Oncology Inc. (CHRS) Company Profile - Business Overview, Management Team & Corporate Information - Stocknear

Coherus Oncology Inc.

NASDAQ: CHRS · Real-Time Price · USD
1.50
0.05 (3.45%)
At close: Sep 26, 2025, 3:59 PM
1.49
-0.67%
After-hours: Sep 26, 2025, 06:58 PM EDT

Company Description

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.

The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27.

It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors.

In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.

It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited.

The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025.

The company was incorporated in 2010 and is based in Redwood City, California.

Coherus Oncology Inc.
Coherus Oncology Inc. logo
Country United States
IPO Date Nov 6, 2014
Industry Biotechnology
Sector Healthcare
Employees 228
CEO Dennis M. Lanfear

Contact Details

Address:
333 Twin Dolphin Drive
Redwood City, California
United States
Website https://www.coherus.com

Stock Details

Ticker Symbol CHRS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001512762
CUSIP Number 19249H103
ISIN Number US19249H1032
Employer ID 27-3615821
SIC Code 2836

Key Executives

Name Position
Dennis M. Lanfear Chairman, President & Chief Executive Officer
Bryan J. McMichael Chief Financial Officer
Andy Rittenberg Executive Vice President of General Counsel
Dr. Rosh Dias M.D., MRCP Chief Medical Officer
Dr. Theresa M. Lavallee Ph.D. Chief Development Officer & Chairman of Scientific Advisory Board
Jodi Sievers Vice President of Investor Relations & Corporate Communications
Michael Chen Senior Vice President of Commercial Analytics & Trade
Rebecca Sunshine Chief Human Resources Officer
Richard L. Hameister Chief Technical Officer
Scott Saywell Executive Vice President of Corporate Development

Latest SEC Filings

Date Type Title
Sep 08, 2025 8-K Current Report
Aug 07, 2025 10-Q Quarterly Report
Aug 07, 2025 8-K Current Report
Jul 03, 2025 8-K Current Report
Jun 13, 2025 4 Filing
Jun 13, 2025 4 Filing
Jun 13, 2025 4 Filing
Jun 13, 2025 4 Filing
Jun 13, 2025 4 Filing
Jun 13, 2025 4 Filing